Tango Therapeutics Executive Chair Barbara Weber Exits with Severance and Full Equity Acceleration
TNGX has more than doubled off its 52-week low of $6.205 on light trading volume (0.3× avg).
Summary
Tango Therapeutics disclosed the executed separation agreement for Executive Chair Barbara Weber, which includes full acceleration of her equity awards and an extended option exercise period, adding material details to her previously announced departure.
Key Events · Executive and Board Changes · TNGX
-
Executive Chair Departure Finalized
Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026, and she resigned from the Board. The separation agreement was executed on August 6, 2026.
-
Severance and Equity Acceleration
Under the agreement, Dr. Weber will receive base salary continuation through December 31, 2026, COBRA reimbursement, full acceleration of all unvested equity awards, and an extended option exercise period until August 3, 2027.
-
Non-Compete Waived, New Restriction Imposed
The company waived the non-compete in her prior restrictive covenant agreement but imposed a new one-year non-compete in the separation agreement, restricting her from competing with Tango's products.
-
Pro-Rated 2026 Bonus
Dr. Weber will receive a pro-rated annual incentive bonus for 2026 based on company and individual performance, to be paid by March 15, 2027.
Analysis · TNGX · Life Sciences
The departure of Executive Chair Barbara Weber is now formalized through a separation agreement that accelerates all her unvested equity awards and extends the option exercise window to August 2027. While the exit itself was disclosed yesterday, the executed agreement unveils significant compensation terms—full vesting acceleration and a one-year non-compete—that could signal either a negotiated exit or potential future competitive moves. With the company recently completing a $600M offering and reporting strong clinical data, leadership stability remains in focus.
At the time of this filing, TNGX was trading at $28.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $6.21 to $34.39. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.